SCHEMBL10073486

SCHEMBL10073486

CC(C)[C@@H]1CC[C@@H](C)C[C@H]1C(=O)Nc1ccc(O)cc1

nearest known ligand 0.75

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 5/20 0.75
EPHX1 P07099 1/20 0.50
DEGS1 O15121 1/20 0.50
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MAPT P10636 2/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TRPV1 Q8NER1 2/20 0.42
ALDH1A1 P00352 3/20 0.42
ALOX15 P16050 1/20 0.42
HTT P42858 1/20 0.42
ESR2 Q92731 1/20 0.42
HSD17B10 Q99714 1/20 0.42
P2RX4 Q99571 1/20 0.41
BLM P54132 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4820732 1.00 TRPM8 (0.75) TRPM8EPHX1DEGS1MEN1KMT2A
SCHEMBL2628672 0.89 TRPM8 (0.75) TRPM8EPHX1MEN1KMT2ANPC1
SCHEMBL4817319 0.89 TRPM8 (0.75) TRPM8EPHX1MEN1KMT2ANPC1
SCHEMBL2628777 0.88 TRPM8 (0.73) TRPM8EPHX1MEN1KMT2ANPC1
SCHEMBL14593913 0.88 TRPM8 (0.73) TRPM8EPHX1MEN1KMT2ANPC1
SCHEMBL4819655 0.88 TRPM8 (0.73) TRPM8EPHX1MEN1KMT2ANPC1
SCHEMBL4820314 0.88 TRPM8 (0.73) TRPM8EPHX1MEN1KMT2ANPC1
SCHEMBL2628747 0.88 TRPM8 (0.73) TRPM8EPHX1MEN1KMT2ANPC1
SCHEMBL10073506 0.88 TRPM8 (0.73) TRPM8EPHX1MEN1KMT2ANPC1
SCHEMBL2628758 0.88 TRPM8 (0.73) TRPM8EPHX1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1656144-B2 TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS GENENTECH INC (US) 2017-12-20 EP disclosed
US-20120045448-A1 TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS GENENTECH, INC. (US) 2012-02-23 US disclosed
US-7893072-B2 Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents GENENTECH, INC. (US) 2011-02-22 US disclosed
US-7893072-B2 Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents GENENTECH, INC. (US) 2011-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120045448-A1 TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS TSG101, TP53, BAX TRPM8 28/4885EPHX1 1033/4885DEGS1 4176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.